Ivette Alarcon
Overview
Explore the profile of Ivette Alarcon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimball A, Bechara F, Badat A, Giamarellos-Bourboulis E, Gottlieb A, Jemec G, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39611771
Background: SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension...
2.
Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, et al.
Front Med (Lausanne)
. 2024 Jul;
11:1403455.
PMID: 39040895
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with a profound disease burden. In recent years, the advent of biologic therapies has improved the treatment landscape for patients with...
3.
Zouboulis C, Passeron T, Pariser D, Wozniak M, Li X, Uhlmann L, et al.
Br J Dermatol
. 2024 Mar;
190(6):836-845.
PMID: 38470171
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with a substantial disease burden. Secukinumab has previously been reported to have sustained efficacy with a favourable safety profile...
4.
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, et al.
J Rheumatol
. 2023 Nov;
51(4):415-422.
PMID: 37914221
Objective: To assess the humoral response to the BNT162b2 mRNA vaccine among patients with spondyloarthritis (SpA) receiving secukinumab (SEC) compared to those receiving tumor necrosis factor inhibitors (TNFi) and immunocompetent...
5.
Armstrong A, Bohannan B, Mburu S, Coates L, Ogdie A, Alarcon I, et al.
Dermatology
. 2023 Apr;
239(4):621-634.
PMID: 37075723
Background: Patients' understanding of the systemic nature of psoriatic disease (PsD) remains insufficiently explored. Objectives: The objective of this study was to assess patients' understanding of PsD, associated comorbidities, disease...
6.
Kirby J, Martorell A, Sayed C, Alarcon I, Kasparek T, Frade S, et al.
Br J Dermatol
. 2023 Apr;
189(2):228-230.
PMID: 37002732
No abstract available.
7.
Roseno N, Lorup E, Richardson C, Alarcon I, Egeberg A
Br J Dermatol
. 2023 Jan;
188(3):372-379.
PMID: 36637104
Background: Comorbidities associated with psoriasis are well documented. However, few studies have explored the comorbidity trajectories that patients with psoriasis commonly experience over time. This study reports the 5-year comorbidity...
8.
Gisondi P, Simon D, Alarcon I, Pournara E, Puig L
J Dermatolog Treat
. 2023 Jan;
34(1):2167487.
PMID: 36625506
There is a paucity of evidence on the impact of immune-mediated inflammatory disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose of this literature review is to address...
9.
Loft N, Skov L, Richardson C, Trivedi V, Alarcon I, Egeberg A
Br J Dermatol
. 2022 Apr;
187(3):353-363.
PMID: 35383888
Background: Patients with psoriasis have a high risk for multiple comorbid conditions. However, few studies have examined the association between psoriasis and severe and rare infections. This study reports the...
10.
Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, et al.
Dermatol Ther (Heidelb)
. 2022 Mar;
12(4):1055-1064.
PMID: 35286611
Introduction: Psoriatic disease (PsD) is a chronic systemic disorder affecting numerous body areas, including skin and joints. Patients' perspectives regarding understanding their disease and dialogue with healthcare professionals (HCPs) on...